2008-06-18 13:51:30 - www.companiesandmarkets.com adds new report - Stakeholder Opinions - Non-Hodgkins Lymphoma - Is there room to emulate Rituxan success

www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Op ..

Introduction

Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.

Scope

NHL background and epidemiology, including forecast incidence of the major subtypes in the seven major markets
Treatment of

NHL by subtype and line of therapy, including major treatment controversies and areas of unmet need
Examination of pipeline activity including profiles of late-phase pipeline drugs
Stakeholder opinions based on qualitative interviews with opinion leaders from the US and Europe

Highlights

Rituxan-based regimens constitute the mainstay of first-line treatment options in several NHL subtypes. Uptake of Rituxan in the maintenance setting for follicular lymphoma (FL) has allowed the drug to achieve further market penetration.

There is a lack of consensus over the treatment of relapsed and refractory disease in most NHL subtypes. Refractory patients are poorly served by currently available treatment options. Other unmet needs include detection of patients with aggressive lymphoma at high risk of relapse and an efficacious maintenance therapy for these patients.

The NHL late-phase pipeline is relatively active, with 10 Phase IIII drugs and 46 Phase II drugs. Monoclonal antibodies are among those agents that continue to demonstrate promising signs of clinical and commercial potential. However, Rituxan's status as market leader is unlikely to be challenged within the next 5 to 10 years.

Reasons to Purchase

Understand current epidemiological trends in non-Hodgkin's lymphoma and ongoing treatment options
Identify limitations of therapy currently available to non-Hodgkin's lymphoma patients and the potential of future therapy
Identify the key products in late-phase development for NHL. Consider, assess and react to opportunities and risks influencing their future potential


www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Op ..